drugset / Trial / NCT02293590

RICE: Remission by Intra-articular Injection Plus CErtolizumab

NCT02293590

Phase 2 Completed 43 enrolled Rüdiger B. Müller UCB Pharma · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

Tight control of an adaptive concomitant treatment strategy after initiation of CZP will lead to an improved outcome of RA patients with an active disease despite DMARD treatment.

Timeline

Start
2013-11
Primary completion
2017-12-22
Completion
2018-01-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Certolizumab Pegol Protein / enzyme biologic 200 mg

Indications